Aromatase Inhibitor-Associated Bone Loss: Clinical Considerations

ISSN： 0012-6667

Source： Drugs, Vol.68, Iss.18, 2008-01, pp. : 2591-2600

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment with aromatase inhibitors for breast cancer is associated with bone loss in postmenopausal women

By Adis International Limited

Drugs & Therapy Perspectives, Vol. 25, Iss. 10, 2009-10 ,pp. : 23-26

Adis International

Access to resources Recommend Favorite

Risedronic acid prevents bone loss in postmenopausal women with breast cancer, with or without aromatase inhibitor (AI) therapy,

Inpharma, Vol. 1, Iss. 1637, 2008-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Management of Protease Inhibitor-Associated Hyperlipidemia

By Penzak S.R.

American Journal of Cardiovascular Drugs, Vol. 2, Iss. 2, 2002-02 ,pp. : 91-106

Adis International

Access to resources Recommend Favorite

Reports of COX-2 inhibitor-associated arrhythmias in NZ

Reactions Weekly, Vol. 1, Iss. 1076, 2005-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Phenytoin associated with bone loss in young women

Reactions Weekly, Vol. 1, Iss. 1200, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite